Obermatt
See Similar Stocks →

Flags

Earnings warning

Cosmo Pharmaceuticals

SWX:COPN · NL0011832936
PharmaceuticalsSmall

360

47
Profit price7
Owner Earnings Yield39
Dividend Yield77
Price/Sales14
EV / Gross Profit12
Price/Book53
Return on Capital25
Cash Return on Capital35
Return on Equity33
EBIT Margin13
Gross Profitability19
Accruals71
Owner Earnings Margin38
Sales growth31
Profit Growth29
Long-Term EPS Growth9
Owner Earnings Growth14
Reinvestment34
Price momentum52
Debt load93
Refinancing56
Debt Payback100
Liquidity12
Analyst ratings100
Opinion Changes50
Price Target Upside84
Market mood29
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cosmo Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryIreland
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeSWX
Founded2016
Employees202
Websitecosmopharma.com
ISINNL0011832936
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
Health DiagnosticsArtificial IntelligenceDermatologyGastroenterologyBiotechnologyHealth CarePharmaceutical

Description

Cosmo N.V. engages in the development and commercialization products for gastroenterology, dermatology, and healthtech. Business Segments The company have identified the pharmaceutical segment as its primary focus, without delineating further sub-s…

Analysis

Middle-of-the-road

Cosmo N.V. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 286.2×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
25
2023202420252026

All-time high

94

Jan 2024

All-time low

16

Feb 2026

Average rank

51

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
14
13
18
7
Price/Earnings
1
75
46
5
Price/Book
53
59
67
85
Dividend Yield
77
82
70
57
Value (overall)
33
46
57
32

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cosmo Pharmaceuticals with its peers
Almirall
MCE:ALM
74
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Sol-Gel Technologies
NAQ:SLGL
36
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Avadel Pharmaceuticals
NMQ:AVDL
70
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →